Adam Davidson, CEO of Trident Royalties, discusses offtake milestones and catalysts to boost FY24. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIMI Regulatory News (IMI)

Share Price Information for IMI (IMI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,803.00
Bid: 1,801.00
Ask: 1,803.00
Change: 38.00 (2.15%)
Spread: 2.00 (0.111%)
Open: 1,788.00
High: 1,805.00
Low: 1,770.00
Prev. Close: 1,765.00
IMI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Proposed acquisition of PBM for $85m

20 Aug 2019 07:00

RNS Number : 5528J
IMI PLC
20 August 2019
 

20 August 2019

IMI announces the proposed acquisition of speciality valve manufacturer PBM for $85m

IMI plc ("IMI" or the "Group") announces the proposed acquisition of PBM Inc., ("PBM") for an enterprise value of $85m (£70.3m1). PBM will become part of IMI's Critical Engineering division. In the year to December 2018, PBM generated revenues of $35.6m (£29.4m), adjusted EBITDA of $6.8m (£5.6m) and adjusted EBIT of $6.3m (£5.2m).The proposed acquisition of PBM is fully aligned with IMI's strategy and represents an important opportunity to broaden IMI Critical Engineering's offering into attractive, adjacent markets. Closing is expected to take place within the next two months, subject to normal merger filings.PBM overviewPBM is a manufacturer of high-quality industrial valves and flow control products. The company is based in Irwin, Pennsylvania, USA and end-markets include Pharmaceutical / Biotechnology, Consumer Products and Chemical. In its largest segment Pharma / Bio, PBM enjoys a leading market position in the US. The company is owned by the senior management team who will remain with the business post-acquisition, apart from the retiring Chairman.

Transaction highlights

Ü

The acquisition extends IMI Critical Engineering's market presence into new, growing segments - including Pharmaceutical / Biotechnology - fully in-line with IMI's stated strategy.

Ü

PBM's reputation for responding quickly to customer needs and developing solutions to industry problems are characteristics that fit well with IMI's operating model.

Ü

PBM enjoys strong distributor and representative relationships - particularly within its main US markets. There are clear opportunities to broaden the market access of both PBM and IMI through their respective routes to market.

Ü

The sharing of best practice between the businesses will facilitate further operational improvement at PBM.

Ü

PBM will be both margin and earnings accretive to IMI.

Ü

The acquisition will deliver a financial return in excess of IMI's cost of capital by the end of year three, before revenue synergies, thereby maintaining the Group's record of strict financial discipline.

 

Commenting on the acquisition, Roy Twite, Chief Executive of IMI, said:"Our strategy at IMI is all about delivering tremendous value by solving industry problems - and putting customers at the heart of our decisions and processes. We are delighted to know that PBM has values and ambitions very similar to our own and I am excited to welcome the company to IMI."Jackie Hu, Divisional Managing Director of IMI Critical Engineering, commented:"I am also thrilled to welcome PBM. The business has fantastic products, a market-leading position and an excellent reputation - particularly in markets that are new to IMI. We are very much looking forward to working with the team and further strengthen and extend our newly combined business."

 

Stuart J. Zarembo, Chairman of the Board and CEO of PBM, added:

"We have built an excellent business at PBM with a great team who are excited about the prospects to develop further as part of a like-minded organisation such as IMI." 

Enquiries to:

John Dean

IMI

Tel: +44 (0)121 717 3712

Suzanne Bartch / Robert Morgan

Teneo

Tel: +44 (0)203 757 9242

 

 

[1] Exchange rate of £1 = US$1.21 as at close of 15 August 2019 (Source: Bloomberg).

Notes to editors

IMI plc

IMI plc, the specialist engineering company, designs, manufactures and services highly engineered products that control the precise movement of fluids. Its innovative technologies, built around valves and actuators, enable vital processes to operate safely, cleanly, efficiently and cost effectively. The Group works with industrial customers across a range of high growth sectors, including energy, transportation and infrastructure, all of which are benefiting from the impact of long-term global trends including climate change, urbanisation, resource scarcity and an ageing population. IMI employs around 11,000 people, has manufacturing facilities in more than 20 countries and operates a global service network. The Company is listed on the London Stock Exchange. Further information is available at: www.imiplc.com.

PBM Inc.

PBM Inc. is a manufacturer of specialty ball valves for sanitary and industrial end-market applications. The Head Office and main manufacturing facility is in Irwin, Pennsylvania, USA and has 104 employees. More information is available at: www.pbmvalve.com.

IMI plc is registered in England No. 714275. Its legal entity identifier ('LEI') number is 2138002W9Q21PF

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
ACQLLFITTRIALIA
Date   Source Headline
26th Jul 20197:00 amRNSInterim Results, six months ended 30 June 2019
15th Jul 20194:29 pmRNSDirector Declaration
10th Jul 20192:03 pmRNSDirector/PDMR Shareholding
4th Jul 20194:07 pmRNSBlock listing Interim Review
1st Jul 201910:35 amRNSTotal Voting Rights
12th Jun 201912:38 pmRNSDirector/PDMR Shareholding
10th Jun 20193:18 pmRNSDirector/PDMR Shareholding
3rd Jun 201910:24 amRNSTotal Voting Rights
20th May 20193:18 pmRNSDirector/PDMR Shareholding
15th May 201912:14 pmRNSDirector/PDMR Shareholding
9th May 20192:05 pmRNSResult of AGM
9th May 20197:00 amRNSInterim Management Statement
1st May 201910:44 amRNSTotal Voting Rights
12th Apr 20193:17 pmRNSDirector/PDMR Shareholding
10th Apr 20193:50 pmRNSDirector/PDMR Shareholding
5th Apr 20199:07 amRNSDirector/PDMR Shareholding
1st Apr 201911:36 amRNSTotal Voting Rights
29th Mar 20194:00 pmRNSDirector/PDMR Shareholding
29th Mar 201911:51 amRNSAnnual Financial Report
18th Mar 20193:56 pmRNSDirector/PDMR Shareholding
13th Mar 201912:12 pmRNSDirector/PDMR Shareholding
7th Mar 20199:25 amRNSHolding(s) in Company
7th Mar 20197:00 amRNSIMI Critical Engineering division - MD appointment
4th Mar 201911:15 amRNSApplication for Block Listing
1st Mar 201910:01 amRNSTotal Voting Rights
1st Mar 20197:00 amRNSPreliminary results, year ended 31 December 2018
1st Mar 20197:00 amRNSCEO succession
26th Feb 20199:23 amRNSHolding(s) in Company
21st Feb 201911:01 amRNSHolding(s) in Company
14th Feb 201911:08 amRNSHolding(s) in Company
13th Feb 201912:40 pmRNSDirector/PDMR Shareholding
12th Feb 201911:26 amRNSHolding(s) in Company
11th Feb 20194:05 pmRNSBlock listing Interim Review
1st Feb 201911:18 amRNSTotal Voting Rights
9th Jan 201912:12 pmRNSDirector/PDMR Shareholding
2nd Jan 201911:17 amRNSTotal Voting Rights
12th Dec 201811:55 amRNSDirector/PDMR Shareholding
3rd Dec 201811:26 amRNSTotal Voting Rights
14th Nov 201810:26 amRNSDirector/PDMR Shareholding
8th Nov 20187:00 amRNSIMI plc Interim Management Statement
18th Oct 201810:35 amRNSHolding(s) in Company
11th Oct 20189:34 amRNSHolding(s) in Company
10th Oct 20182:38 pmRNSDirector/PDMR Shareholding
1st Oct 201812:27 pmRNSTotal Voting Rights
24th Sep 20188:59 amRNSDirector/PDMR Shareholding
17th Sep 20182:57 pmRNSDirector/PDMR Shareholding
12th Sep 20182:23 pmRNSDirector/PDMR Shareholding
3rd Sep 20184:05 pmRNSTotal Voting Rights
16th Aug 20182:09 pmRNSDirector/PDMR Shareholding
15th Aug 201812:04 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.